Hayashi Y, Widjono YW, Ohta K, Hanioka K, Obayashi C, Itoh K, Imai Y, Itoh H

Expression of EGF, EGF-receptor, p53, v-erb B and ras p21 in colorectal neoplasms by immunostaining paraffin-embedded tissues.

Pathol Int 44:124-30 (1994)
DOI:10.1111/j.1440-1827.1994.tb01696.x

Spano JP, Fagard R, Soria JC, Rixe O, Khayat D, Milano G

Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives.

Ann Oncol 16:189-94 (2005)
DOI:10.1093/annonc/mdi057

Breuhahn K, Longerich T, Schirmacher P

Dysregulation of growth factor signaling in human hepatocellular carcinoma.

Oncogene 25:3787-800 (2006)
DOI:10.1038/sj.onc.1209556

Kiss A, Wang NJ, Xie JP, Thorgeirsson SS

Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas.

Clin Cancer Res 3:1059-66 (1997)

Yarden Y, Sliwkowski MX.

Untangling the ErbB signalling network.

Nat Rev Mol Cell Biol 2:127-37 (2001)
DOI:10.1038/35052073

Di Fiore F, Sesboue R, Michel P, Sabourin JC, Frebourg T

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer.

Br J Cancer 103:1765-72 (2010)
DOI:10.1038/sj.bjc.6606008

Jing C, Jin YH, You Z, Qiong Q, Jun Z

Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients.

Oncotarget 7:55890-55899 (2016)
DOI:10.18632/oncotarget.10151

Li XD, Miao SY, Wang GL, Yang L, Shu YQ, Yin YM

Amphiregulin and epiregulin expression in colorectal carcinoma and the correlation with clinicopathological characteristics.

Onkologie 33:353-8 (2010)
DOI:10.1159/000315380

Di Fiore F, Sesboue R, Michel P, Sabourin JC, Frebourg T

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer.

Br J Cancer 103:1765-72 (2010)
DOI:10.1038/sj.bjc.6606008

Jing C, Jin YH, You Z, Qiong Q, Jun Z

Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients.

Oncotarget 7:55890-55899 (2016)
DOI:10.18632/oncotarget.10151

Li XD, Miao SY, Wang GL, Yang L, Shu YQ, Yin YM

Amphiregulin and epiregulin expression in colorectal carcinoma and the correlation with clinicopathological characteristics.

Onkologie 33:353-8 (2010)
DOI:10.1159/000315380

Whittaker S, Marais R, Zhu AX

The role of signaling pathways in the development and treatment of hepatocellular carcinoma.

Oncogene 29:4989-5005 (2010)
DOI:10.1038/onc.2010.236

Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A

An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis.

Biochem Pharmacol 68:1003-15 (2004)
DOI:10.1016/j.bcp.2004.05.029

Minguez B, Tovar V, Chiang D, Villanueva A, Llovet JM

Pathogenesis of hepatocellular carcinoma and molecular therapies.

Curr Opin Gastroenterol 25:186-94 (2009)
DOI:10.1097/MOG.0b013e32832962a1

Breuhahn K, Longerich T, Schirmacher P

Dysregulation of growth factor signaling in human hepatocellular carcinoma.

Oncogene 25:3787-800 (2006)
DOI:10.1038/sj.onc.1209556

Minguez B, Tovar V, Chiang D, Villanueva A, Llovet JM

Pathogenesis of hepatocellular carcinoma and molecular therapies.

Curr Opin Gastroenterol 25:186-94 (2009)
DOI:10.1097/MOG.0b013e32832962a1

Whittaker S, Marais R, Zhu AX

The role of signaling pathways in the development and treatment of hepatocellular carcinoma.

Oncogene 29:4989-5005 (2010)
DOI:10.1038/onc.2010.236